The discovery and potency optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. Micromolar hits taken from high-throughput screening were optimized for biochemical and cellular mechanistic potency to ~10nM, as exemplified by compound 12az. Application of structure-based drug design aided by co-crystal structures of TAK1 with inhibitors significantly shortened the number of iterations required for the optimization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2013.06.053 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!